

NEJM-17-00312.R4

## **Supplementary Appendix**

### **Nutritional Management of Chronic Kidney Disease**

**Kamyar Kalantar-Zadeh, M.D., M.P.H., Ph.D.,<sup>1-4</sup> and Denis Fouque, M.D., Ph.D.<sup>5</sup>****From:**

- (1) Harold Simmons Center of Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange & Irvine, CA
- (2) Long Beach VA Healthcare System, Long Beach, CA
- (3) Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA
- (4) Dept. Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA
- (5) Univ. Lyon, UCBL, Department of Nephrology, Centre Hospitalier Lyon Sud, CarMen, CENS, F-69622, Lyon, France

**Table of Content**

A. Supplementary Appendix Tables:	
Table S1: Limitation of the MDRD Study	Page 2
Table S2: Selected controlled trials	Page 3-5
Table S3: Ranges of dietary protein intake	Page 6
Table S4: Features of CKD diet and food frequency	Page 7
Table S5: Additional dietary recommendations	Page 8
B. Supplementary Appendix Figures:	
Figure S1: Secondary analyses of the MDRD Study	Page 9
Figure S2: Risks/benefits of dietary protein intake levels	Page 10
Figure S3: Gastrointestinal tract and uremic toxins	Page 11
Figure S4: Algorithm for CKD nutritional management	Page 12
C. Supplementary Appendix Textboxes:	
Box S1: Symptoms across CKD stages	Page 13
Box S2: Meal recipe from the USA	Page 14
Box S3: Meal recipe from France	Page 15-16
D. Supplementary Appendix References:	
References 1 through 25	Pages 17-18

**Supplementary-Appendix-Table S2.** Selected controlled trials (with greater than 30 participants) that have examined the effects of low-protein or very low-protein diets (with or without supplementation with ketoacids or amino-acids) on various outcome measures in patients with chronic kidney disease.

Study (Year)	Participants	Dietary Intervention	Outcomes	Follow-Up Time	Results	Comment
Rosman et al (1984) <sup>6,7</sup>	247 pts with CKD 3-5	0.90-0.95 g/kg/day (CKD 3) vs. 0.70-0.80 g/kg/day (CKD 4-5) vs. unrestricted DPI	GFR after 2 or 4 years	4 years	After 2 years significant slowing of CKD progression in LPD, but only in male pts.	4-year renal survival improvement in LPD (60% vs. 30%, $p < 0.025$ ). PKD pts did not respond to LPD.
Ihle et al (1989) <sup>8</sup>	72 pts with CKD 4-5	LPD (0.6 g/kg/day) vs. higher DPI (0.8 g/kg/day)	GFR every 6 mos	18 mos	Stable GFR in LPD vs. loss of GFR in control group ( $p < 0.05$ ).	LPD pts lost weight but no change in anthropometric measures or serum albumin.
Lindenau et al (1990) <sup>9</sup>	40 pts with CKD 5 (GFR < 15 ml/min/1.73m <sup>2</sup> )	LPD with calcium suppl. (n=18) vs. sVLPD (0.4 g/kg) with KA (n=22)	Bone and mineral markers including via bone biopsies	12 mos	Decreased serum phosphorus with sVLPD, improved markers of bone breakdown in bone biopsies in sVLPD group.	CKD progression and other outcomes not assessed.
Williams et al (1991) <sup>10</sup>	95 pts with CKD 4-5	LPD (0.7 g/kg/day) vs. normal diet (DPI 1.02 and 1.14 g/kg/day), and varied phos content	CKD progression rates across 3 groups	18 mos	No differences in the reduction in creatinine clearance, dialysis initiation or mortality among 3 groups.	Minor weight loss in LPD.
Locatelli et al (1991) <sup>11</sup>	456 pts CKD 3-4	LPD (0.78 g/kg/day) vs. normal DPI (0.9 g/kg/day), both DEI > 30 Cal/kg/day	Renal survival defined as dialysis start or doubling of serum creatinine	2 years	Borderline difference, slightly fewer pts assigned to LPD group reached the endpoint ( $p = 0.059$ ).	Substantial overlap in DPI between 2 groups.
MDRD Study 2 Klahr et al (1994) <sup>1</sup>	255 pts with CKD 4-5 (GFR 13-24)	LPD (0.6 g/kg/day) vs. sVLPD (0.3 g/kg/day with KA)	CKD progression, blood pressure, proteinuria, nutrition	27 mos	sVLPD group had a marginally slower decline in GFR than LPD group ( $P = 0.067$ ). Higher calcium, lower phos,	2 concurrent randomized controlled trials. Serum albumin increased in both

	ml/min/1.73 m <sup>2</sup> )			(mean follow-up)	alkaline phosphatase, and PTH levels in sVLPD group.	sVLPD and LPD groups and did not differ between groups.
MDRD Study 1 Klahr et al (1994) <sup>1</sup>	585 pts with CKF 3-4 (GFR 25-55 ml/min/1.73m <sup>2</sup> )	usual-protein diet (DPI 1.3 g/kg/day) vs. LPD (0.6 g/kg/day)	CKD progression, blood pressure, proteinuria, nutrition	27 mos (mean follow-up)	Projected mean GFR decline at 3 years did not differ significantly between the diet groups. Faster GFR decline in the first 4 mos in the LPD group.	2 concurrent randomized controlled trials. Serum albumin increased in both sVLPD and LPD groups and did not differ between groups.
Montes-Delgado et al (1998) <sup>12</sup>	33 pts with CKD 3-5	LPD vs. LPD suppl. with a low-protein and hypercaloric supplement	Renal function and nutritional status	6 mos	Slower CKD progression in the supplemented group, with better nutritional status and higher adherence.	22 patients completed the full 6-mo study.
Malvy et al (1999) <sup>13</sup>	50 pts with CKD 4-5 (eGFR < 20 ml/min/1.73m <sup>2</sup> )	sVLPD (0.3 g/kg/day) with KA vs. LPD (0.65 g/kg/day)	3 mo to eGFR > 5 ml/min/1.73m <sup>2</sup> or need for dialysis	3 years	SUN, lean body mass and fat mass decreased in sVLPD group.	Randomized trial. No difference in renal survival, sVLPD pts lost 2.7 kg (both fat and lean body mass).
Teplan et al (2001) <sup>14</sup>	105 CKD pts (GFR 22-36 ml/min/1.73m <sup>2</sup> )	LPD with KA and EPO vs. LPD without KA (with/without EPO)	CKD progression rate and nutritional measures	3 years	sLPD with KA/EPO showed slower CKD progression and increased leucine, isoleucine, valine and mild decrease in proteinuria (p < 0.01).	Role of EPO remained unclear.
Prakash et al (2004) <sup>15</sup>	34 CKD pts (mean eGFR 28 ml/min/1.73m <sup>2</sup> )	LPD (0.6 g/kg/day) with placebo vs. sVLPD (0.3 g/kg/day with KA)	Changes in GFR and nutritional markers	9 mos	Stable GFR in the sVLPD vs. worsening nutritional measures and faster GFR decline in LPD group.	Prospective, randomized, double-blind, placebo-controlled single center trial.
Brunori et al (2007) <sup>16</sup>	56 non-diabetic pts (>70 yrs old) CKD 5 (GFR 5-7 ml/min/1.73m <sup>2</sup> )	sVLPD (DPI: 0.3 g/kg/day, DEI: 35 Cal/kg/d) with KA, vs. dialysis initiation	Survival, hospitalization, and metabolic markers.	Median time 26.5 mos	Similar survival in both groups. Patients assigned to dialysis had a 50% higher degree of hospitalization.	There was a continuous benefit of LPD over time.

Mircescu et al (2007) <sup>17</sup>	53 non-diabetic CKD 4-5 pts (eGFR<30 ml/min/1.73m <sup>2</sup> )	sVLPD (0.3 g/kg/day vegetable proteins) suppl. with KA vs. LPD	Transition to dialysis, eGFR, and laboratory markers	48 weeks	Less dialysis initiation with sVLPD (4% vs. 27%). Stable eGFR in sVLPD group, but decreased eGFR in controls.	Open-label randomized, controlled trial. Higher bicarbonate and lower phos in sVLPD group.
Cianciaruso et al (2008) <sup>18</sup>	423 pts with CKD 4-5	2 different DPI levels 0.55 (n=212) vs. 0.80 g/kg/day (n=211)	CKD progression, and changes in blood and urinary biomarkers.	18 mos	Reduced urinary excretion of urea, sodium, phos in LPD. No differences in phos, albumin, PTH, bicarbonate. No changes in body composition.	Estimated DPI in low vs. high groups were 0.72 vs. 0.92 g/kg/day (p< 0.05). 9 vs 13 pts in LPD vs higher DPI stated dialysis.
Di Iorio et al (2009) <sup>19</sup>	32 CKD pts with proteinuria	VLPD vs. LPD	Changes in urinary protein and AGE.	6 mos	58% more reduction in urinary protein excretion and in serum AGE level in VLPD.	Prospective randomized controlled cross-over trial.
Jiang et al (2009 and 2011) <sup>20,21</sup>	60 new ESRD pts on PD with RKF	LPD vs. sLPD (LPD + ketoacids) vs. HPD	RKF and nutritional markers on PD	12 mos	RKF stable in sLPD group but decreased in the LPD and HPD groups.	No change from baseline on nutritional status in any of the groups during follow-up.
Garneata et al (2016) <sup>22</sup>	207 non-diabetic pts with CKD 4-5 (eGFR <30 ml/min/1.73m <sup>2</sup> ) and proteinuria <1 g/day	LPD (0.6 g/kg/day) vs. sVLPD (vegetarian VLDL 0.3 g/kg/day with KA)	Dialysis initiation or 50% reduction in initial eGFR	15 months	Adjusted NNT (95% CI) to avoid dialysis was 22.4 (21.5-25.1) for pts with eGFR<30 ml/min/1.73m <sup>2</sup> but decreased to 2.7 (2.6-3.1) for pts with eGFR<20 ml/min/1.73m <sup>2</sup> in ITT analysis.	Correction of metabolic abnormalities occurred only with sVLPD. Compliance to diet was good, with no changes in nutritional measure.

**Abbreviations:** AA, amino-acid; AGE, advanced glycation end products; CKD, chronic kidney disease; DEI, dietary energy intake; DPI, dietary protein intake; eGFR, estimated glomerular filtration rate; EPO, recombinant human erythropoietin; EAA: Essential amino-acids; GFR, estimated glomerular filtration rate; HPD, high-protein diet; ITT: intention to treat; KA: ketoacids supplement; LPD, low-protein diet; mos, months; NNT: number needed to treat; PD, peritoneal dialysis; PEW: protein-energy wasting; phos, phosphorus; PKD, polycystic kidney disease; pt: patient; pts: patients; RKF, residual kidney function; sLPD, supplemented low-protein diet; SUN, serum urea nitrogen; sVLPD, supplemented very low-protein diet; VLPD, very low-protein diet.

## **D. Supplementary-Appendix References:**

1. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994;330:877-84.
2. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. *Hypertension* 1997;30:428-35.
3. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. *J Am Soc Nephrol* 1999;10:2426-39.
4. Levey AS, Greene T, Sarnak MJ, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. *Am J Kidney Dis* 2006;48:879-88.
5. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med* 1995;123:754-62.
6. Rosman JB, ter Wee PM, Meijer S, Piers-Becht TP, Sluiter WJ, Donker AJ. Prospective randomised trial of early dietary protein restriction in chronic renal failure. *Lancet* 1984;2:1291-6.
7. Rosman JB, Langer K, Brandl M, et al. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. *Kidney Int Suppl* 1989;27:S96-102.
8. Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-Smith PS. The effect of protein restriction on the progression of renal insufficiency. *N Engl J Med* 1989;321:1773-7.
9. Lindenau K, Abendroth K, Kokot F, Vetter K, Rehse C, Frohling PT. Therapeutic effect of keto acids on renal osteodystrophy. A prospective controlled study. *Nephron* 1990;55:133-5.
10. Williams PS, Stevens ME, Fass G, Irons L, Bone JM. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. *Q J Med* 1991;81:837-55.
11. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. *Lancet* 1991;337:1299-304.
12. Montes-Delgado R, Guerrero Riscos MA, Garcia-Luna PP, et al. [Treatment with low-protein diet and caloric supplements in patients with chronic kidney failure in predialysis. Comparative study]. *Rev Clin Esp* 1998;198:580-6.
13. Malvy D, Maingourd C, Pengloan J, Bagros P, Nivet H. Effects of severe protein restriction with ketoanalogues in advanced renal failure. *J Am Coll Nutr* 1999;18:481-6.
14. Teplan V, Schuck O, Knotek A, et al. Effects of low-protein diet supplemented with ketoacids and erythropoietin in chronic renal failure: a long-term metabolic study. *Ann Transplant* 2001;6:47-53.
15. Prakash S, Pande DP, Sharma S, Sharma D, Bal CS, Kulkarni H. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. *J Ren Nutr* 2004;14:89-96.
16. Brunori G, Viola BF, Parrinello G, et al. Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study. *Am J Kidney Dis* 2007;49:569-80.
17. Mircescu G, Garneata L, Stancu SH, Capusa C. Effects of a supplemented hypoproteic diet in chronic kidney disease. *J Ren Nutr* 2007;17:179-88.
18. Cianciaruso B, Pota A, Pisani A, et al. Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. *Nephrol Dial Transplant* 2008;23:636-44.

19. Di Iorio BR, Cucciniello E, Martino R, Frallicciardi A, Tortoriello R, Struzziero G. [Acute and persistent antiproteinuric effect of a low-protein diet in chronic kidney disease]. *G Ital Nefrol* 2009;26:608-15.
20. Jiang N, Qian J, Sun W, et al. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective, randomized trial. *Nephrol Dial Transplant* 2009;24:2551-8.
21. Jiang N, Qian J, Lin A, et al. Low-protein diet supplemented with keto acids is associated with suppression of small-solute peritoneal transport rate in peritoneal dialysis patients. *International journal of nephrology* 2011;2011:542704.
22. Garneata L, Stancu A, Dragomir D, Stefan G, Mircescu G. Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. *J Am Soc Nephrol* 2016;27:2164-76.
23. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int* 2008;73:391-8.
24. de Jong PE, Anderson S, de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome? *J Am Soc Nephrol* 1993;3:1333-41.
25. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011;80:17-28.